The experience of interleukin-1 inhibition in patients with familial Mediterranean fever

Authors : Demet YALÇIN KEHRİBAR, Metin ÖZGEN

Pages : 27-31

View : 40 | Download : 15

Publication Date : 2021-01-26

Article Type : Research Paper

Abstract :This study aimed to present our single-center experience of anakinra and canakinumab treatment in patients with Familial Mediterranean fever insert ignore into journalissuearticles values(FMF);. This study included 48 patients who were treated with anti-interleukin-1 insert ignore into journalissuearticles values(antiIL-1); treatment for at least six months. Initially, all patients with colchicineresistant or intolerant FMF were received anakinra treatment. Then those resistant to anakinra were given canakinumab treatment. Of the 48 insert ignore into journalissuearticles values(female/male:29/19); patients using anti-IL-1, their age was 31.2 ± 10.7 years, the duration of drug use was 15±8 months. 30 patients were already using anakinra and 18 patients were using canakinumab. Treatment was found to be switched to canakinumab in 9 patients due to non-adherence to daily injection, and inadequate response to anakinra in 9 patients. After the anti-IL-1 treatment the number of attacks, erythrocyte sedimentation rate, C-reactive protein, fibrinogen levels, colchicine dose and proteinuria insert ignore into journalissuearticles values(for all p<0.001); were decreased. Anti-IL-1 treatment is effective for controlling attacks and reducing proteinuria in patients with colchicine-resistant or intolerant FMF. In addition, canakinumab appears to be an alternative treatment option when there is a inconvenience to daily injection or resistance to anakinra treatment.
Keywords : familial Mediterranean fever, interleukin 1 inhibition, anakinra, canakinumab

ORIGINAL ARTICLE URL